Sheng Zhang

Prof. Sheng Zhang

Department of Stomatology, Second Xiangya Hospital, Central South University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
BDBo-Wen Dai
Bo-Wen Dai
ZYZhi-Min Yang
Zhi-Min Yang
PDPing Deng
Ping Deng
YCYan-Rong Chen
Yan-Rong Chen
ZHZhi-Jing He
Zhi-Jing He
ZRZhen-Hu Ren
Zhen-Hu Ren
As a master regulator of embryonic morphogenesis, homeodomain-containing gene 10 (HOXC10) has been found to promote progression of human cancers and indicate poor survival outcome. Therefore, we concentrate on elucidating the role of HOXC10 in progression of oral squamous cell carcinoma (OSCC). In our study, the expression of HOXC10 was significantly increased in human OSCC samples and was significantly correlated with TNM stage and lymph node metastasis. Upregulation of HOXC10 indicated a poor overall survival of OSCC patients according to the Kaplan-Meier survival curves. Furthermore, HOXC10-knockdown dramatically suppressed migration, invasion, and expression of N-Cadherin, Vimentin and Snail, as well as increased E-cadherin level both in vivo and in vitro. Bioinformatics and cellular study further confirmed that HOXC10 may promote invasion and migration of OSCC cells by regulating the WNT/epithelial-mesenchymal transition (EMT) signaling pathway. These findings suggest that HOXC10 plays a pivotal role in the metastasis of OSCC and highlight its usefulness as a potential prognostic marker or therapeutic target in human OSCC.

21 September 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LZLiang Zhong
Liang Zhong
YLYutong Liu
Yutong Liu
KWKai Wang
Kai Wang
ZHZhijing He
Zhijing He
ZGZhaojian Gong
Zhaojian Gong
LCLin Chen
Lin Chen
Traditional therapeutics have encountered a bottleneck caused by diagnosis delay and subjective and unreliable assessment. Biomarkers can overcome this bottleneck and guide us toward personalized precision medicine for oral squamous cell carcinoma. To achieve this, it is important to efficiently and accurately screen out specific biomarkers from among the huge number of molecules. Progress in omics-based high-throughput technology has laid a solid foundation for biomarker discovery. With credible and systemic biomarker models, more precise and personalized diagnosis and assessment would be achieved and patients would be more likely to be cured and have a higher quality of life. However, this is not straightforward owing to the complexity of molecules involved in tumorigenesis. In this context, there is a need to focus on tumor heterogeneity and homogeneity, which are discussed in detail. In this review, we aim to provide an understanding of biomarker discovery and application for precision medicine of oral squamous cell carcinoma, and have a strong belief that biomarker will pave the road toward future precision medicine.

30 August 2021 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
KWKun Wu
Kun Wu
YMYuan-Yuan Mao
Yuan-Yuan Mao
QCQi Chen
Qi Chen
BZBolin Zhang
Bolin Zhang
SZSheng Zhang
Sheng Zhang
YLYan Li
Yan Li

1 October 2019 in Toxicology Letters
Verified
Journal Article
Closed access
TFTengfei Fan
Tengfei Fan
YCYanrong Chen
Yanrong Chen
ZHZhijing He
Zhijing He
QWQing Wang
Qing Wang
XYXi Yang
Xi Yang
SZSheng Zhang
Sheng Zhang

19 January 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YPYongchun Peng
Yongchun Peng
DYDanhui Yin
Danhui Yin
XLXiaoxuan Li
Xiaoxuan Li
KWKai Wang
Kai Wang
WLWei Li
Wei Li
TFTengfei Fan
Tengfei Fan

18 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KWKun Wu
Kun Wu
YMYuan-Yuan Mao
Yuan-Yuan Mao
NHNan-Nan Han
Nan-Nan Han
HWHanjiang Wu
Hanjiang Wu
SZSheng Zhang
Sheng Zhang
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignant neoplasm; it is associated with high morbidity and mortality. Thus, understanding the molecular mechanisms underlying its initiation and progression is critical for establishing the most appropriate treatment strategies. We found that urokinase-type plasminogen activator (PLAU1) was upregulated and associated with poor prognosis in HNSCC. Silencing of PLAU1 inhibited the proliferation, colony-formation, migration, and invasion abilities of HNSCC cells in vitro and reduced the expression of matrix metalloproteinase 1 (MMP1), whereas PLAU1 overexpression significantly enhanced the growth, the colony-formation, migration, and invasion abilities, and the xenograft tumor growth of HNSCC cells in vivo and increased the expression of MMP1. The Co-IP assay verified that PLAU1 interacted with MMP1. A positive correlation between PLAU1 and MMP1 expression was observed in HNSCC samples. si-RNAs against MMP1 reversed the aggressive effects of PLAU1 overexpression in HNSCC. Taken together, our data revealed that PLAU1 facilitated HNSCC cell proliferation, invasion, and metastasis via interaction with MMP1.